Alectinib in terms of overall response rate, progression-free survival and partial response is superior to crizotinib in the treatment of ALK-positive non-small cell lung cancer and is well tolerated. Compared with crizotinib, alectinib is more effective than crizotinib and has a lower incidence of total adverse reactions. Meta-analysis results confirm the strong base for alectinib as a first-line treatment for ALK-positive NSCLC. READ ARTICLE
Frontiers in Oncology DOI: 10.3389/fonc.2021.646526
Authors: Hao Tang, Longyu Jin, Zhang Zhang, Zhibin Jiang and Zeeshan Malik